VRTX Inaxaplin Cuts Proteinuria 42.7% in AMKD

Vertex wants you to believe it is building a third growth leg. Cystic fibrosis is the first, a franchise that still generates the bulk of Vertex’s roughly $12 billion in annual revenue and is not going anywhere. The pain program built around suzetrigine, plus the $10 billion Crinetics acquisition, is the second. The third is the kidney, and on September 22 Vertex dropped the latest evidence for it: positive Phase 2b data for inaxaplin, its first-in-class APOL1 inhibitor, in two populations of APOL1-mediated kidney disease (AMKD) that the registrational trial does not cover. The data is good. The binary is still a year away.

To be precise about what “positive” means here, because Vertex’s press release and the headlines disagree. The AMPLIFIED study enrolled 41 people across two single-arm cohorts and measured the percent change in urine albumin-to-creatinine ratio (UACR) at week 13. In cohort 1, people with AMKD and modest proteinuria, inaxaplin cut UACR by 42.7% (95% CI -58.3% to -21.1%). That is a clean result, and it is nearly identical to the 43.4% UACR reduction Vertex reported from the earlier Phase 2a study in AMKD with focal segmental glomerulosclerosis. In cohort 2, people with AMKD and type 2 diabetes, inaxaplin cut UACR by 17.3%, but the confidence interval (-36.3% to +7.2%) crosses zero. That cohort missed statistical significance. Vertex’s chief medical officer called the modest-proteinuria result “remarkable” and said the team is “excited” by the smaller diabetes effect. It is the other way around: the modest-proteinuria data is the real signal, and the diabetes data is a coin flip Vertex hopes to win later.

The disease backdrop is why this matters at all. AMKD is caused by two variants in the APOL1 gene that are common in people of African ancestry, and it produces rapidly progressive, proteinuric kidney disease that ends in dialysis, transplant, or death. Vertex estimates roughly 150,000 people in the U.S. and Europe have the disease, and there are zero approved treatments. Every one of those patients is currently managed with generic blood-pressure and diabetes drugs that slow the decline but do not touch the underlying APOL1 biology. Inaxaplin, a small molecule that inhibits APOL1 channel function, is the first drug designed to hit the cause. The Phase 2a and now the Phase 2b modest-proteinuria data both show a roughly 43% UACR reduction on top of standard of care, which is exactly the kind of proteinuria signal the FDA has accepted as a surrogate for accelerated approval in other kidney diseases.

The biology is worth one more sentence, because it is the reason the biomarker matters. APOL1 is expressed in podocytes, the cells that form the kidney’s filtration barrier, and the two risk variants make those cells leaky and prone to death. Proteinuria is the direct downstream readout of that damage, which is why a drug that reduces UACR is plausibly hitting the root cause rather than masking symptoms. That is the logic the FDA uses when it grants accelerated approval on a proteinuria surrogate, and it is the reason Vertex is confident enough to run a 466-patient confirmatory trial rather than a smaller registration study. Inaxaplin also sits beside programs in polycystic kidney disease and primary membranous nephropathy, so a win in AMKD feeds a broader renal franchise that is already taking shape.

The real catalyst is AMPLITUDE, the Phase 2/3 trial in roughly 466 people with severe proteinuria and no other kidney disease. Its primary endpoint is the slope of estimated glomerular filtration rate (eGFR) over two years, a hard functional endpoint, not a biomarker. Enrollment is complete, and Vertex says the pre-planned interim analysis reads out in early 2027, once the cohort reaches 48 weeks of treatment. If that interim is positive, it could support a filing for accelerated approval. This is the binary, and everything before it is stage-setting.

What does the interim need to show to move Vertex? A statistically significant separation on eGFR slope, or at minimum a proteinuria reduction large enough and durable enough that the FDA accepts it as reasonably likely to predict clinical benefit. The Guggenheim team put the probability of success in primary AMKD at 65%, which feels about right for a mechanism with clean Phase 2a and Phase 2b biomarker data but no long-term hard-endpoint proof yet. The diabetes population is a longer shot at 45%, and that is the cohort where inaxaplin’s effect was weakest.

The competitive picture is thin, and that is both the bull case and the risk. The only other serious APOL1 program is Maze Therapeutics’ MZE829, a dual-mechanism APOL1 inhibitor in Phase 2. Maze is a $1.58 billion company trading at $28.09, and it rallied on the Vertex readout, because a clean Vertex result validates the whole APOL1 class. Here is the sharpest way to frame it: Maze is the pure-play APOL1 bet and Vertex is the diversified giant. If you want high-beta exposure to AMKD, Maze at $1.58 billion is the vehicle. If you want the safety of a company that can survive an inaxaplin miss without flinching, Vertex at $130 billion is the vehicle. Vertex’s kidney push already includes povetacicept in IgA nephropathy, which carries a November 30 PDUFA covered in the povetacicept primer and the Q2 earnings breakdown. Inaxaplin is the second leg of that kidney franchise, and the broader nephrology catalyst map is worth tracking if you want the full picture.

The risks are the usual ones for single-arm Phase 2 data, plus a few specific to this program. The cohorts are tiny: 22 and 17 patients in the efficacy analyses, with post-hoc confidence intervals. The diabetes cohort’s null result is a warning that inaxaplin’s effect is not uniform across AMKD subpopulations, which matters if Vertex tries to claim a broad label. Five patients had asymptomatic transaminase elevations that resolved, a minor liver signal worth watching in a drug meant to be taken chronically. And the immateriality problem is real: even a $1 billion peak-sales AMKD franchise is under 1% of Vertex’s $130 billion market cap, so inaxaplin will never move the stock the way Trikafta did or suzetrigine could. There is also the accelerated-approval trap: if the FDA grants approval on the proteinuria surrogate and the final two-year eGFR slope data later misses, Vertex would face a confirmatory-trial showdown with the regulator, and the label could be pulled. That is a tail risk, but it is the specific failure mode to watch for a drug built on a biomarker.

So how to play it? Vertex is a hold, not a buy for inaxaplin. The kidney thesis is progressing exactly as Vertex promised, and the modest-proteinuria data de-risks the mechanism without de-risking the approval. If you want the AMKD catalyst, Maze is the higher-beta expression, but it is also a single-asset company that will crater on a bad Phase 2 readout. For Vertex holders, inaxaplin is a free call option on a disease with no approved treatment and 150,000 patients, and the honest position is to wait for the AMPLITUDE interim in early 2027 before assigning it any value. If the interim hits, inaxaplin becomes the first drug in a market with zero competition, and Vertex gets its third growth leg. The re-rating math is simple: AMKD is a $1 billion-plus opportunity where the only alternatives are generic supportive care, and Vertex would be the first mover. For a company at $130 billion that is not a stock-moving event, but it is the difference between a kidney franchise with two legs and one with one. If it misses, Vertex shrugs and Maze takes the real damage. Position sizing: 1-2% of a biotech portfolio in the pure play, or nothing at all in Vertex for this specific catalyst.